06826.HK
Shanghai Haohai Biological Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 16.73
−0.36%Aug 21, 2026, 10:34 UTC
Shanghai Haohai Biological Technology Co., Ltd. announced its first-half 2026 results: net profit attributable to shareholders was 113 million yuan, down 46.64% year-on-year.
Source:Aug 21, 2026, 10:34 UTC
Shanghai Haohai Biological Technology Co., Ltd. announced a cash dividend of 2.5 yuan per 10 shares (tax inclusive), totaling 56.1875 million yuan (tax inclusive).
Source:Aug 6, 2026, 09:10 UTC
Haohai Shengye's controlled subsidiary Saimaishi obtained a product registration certificate from the National Medical Products Administration for a trifocal toric intraocular lens, applicable to aphakic vision correction in adult cataract patients with corneal astigmatism, valid until August 3, 2031.
Source: